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2SUMMARY (ABSTRACT)
Candidate’s Surname: Berry 
Candidate’s Forename: Sandeep 
Candidate for the Degree of MPhil
Title of Thesis: Identification of dead regions within the Cochlea using Threshold 
Equalizing noise test (TEN) in patients who had chemotherapy with platinum based 
drugs.
SUMMARY
(A) OBJECTIVE
To assess if platinum based chemotherapy causes dead regions in Cochlea
(B) METHODS
STUDY DESIGN 
Prospective & longitudinal 
YEAR OF STUDY
2005 -2009 (Part time as part of MPhil, University of Swansea)
DISEASE/ CONDITION STUDIED
Patients having chemotherapy with platinum chemotherapeutic drugs (Cisplatin, 
Carboplatin & Oxaliplatin) would be included and their hearing assessed by 
threshold equalising noise (HL) test for the presence of dead regions before initiation 
of therapy and then at 1, 6 & 12 months post treatment.
SUBJECTS STUDIED 
50 patients were included.
Inclusions:
■ Age 20-75 years, both male and female patients
■ On chemotherapeutic agents
❖ cisplatin (n= 19)
♦> carboplatin (n= 20)
❖ oxaliplatin (n= 11)
3Exclusions:
■ Middle or outer ear disease causing conductive hearing loss
■ On other ototoxic drugs (past or present)
■ Congenital hearing loss
■ Patients who do not, or are unable to, consent to the trial
■ Terminally ill patients
SETTING IN WHICH SUBJECTS STUDIED
TEN test was performed in a sound proof room within the Audiology department at 
Singleton hospital, Swansea.
INTERVENTION 
Threshold Equalising noise test
OUTCOME MEASUREMENT 
Identification of Dead region
(C) RESULTS
A total of seven subjects demonstrated dead regions, of which three had received 
Oxaliplatin, two received Cisplatin and two received Carboplatin. Another five 
subjects showed evidence of dead region at pre- chemotherapy stage, none of them 
had any previous history of chemotherapy with platinum based drugs, loud noise 
exposure, radiotherapy or use of ototoxic drugs. On reviewing the literature (search 
strategy: Oxaliplatin AND / OR hearing loss: 1966 to date), there has been only one 
report of a case of Oxaliplatin induced hearing loss.
(D) CONCLUSION
This study highlighted that administration of platinum based drugs leads to dead 
regions albeit at variable times. Dead regions can improve spontaneously and were 
also associated with use of Oxaliplatin.
Key words: TEN test; dead regions; platinum drugs
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1.1 Rationale
Cochlear hearing loss can arise from different causes and is often associated with 
damage to hair cells within the cochlea. Inner hair cells (IHC) at certain places along 
the basilar membrane may be non-functional or even missing thereby leading to no 
transduction of basilar membrane vibration at those places. In addition to the above, 
the auditory neurons associated with certain places may be non-functioning or 
degenerated. This means that the information about basilar membrane vibration at 
those places is not transmitted to the brain.
The pattern of damage to IHC is never mentioned in the literature in human models 
because it was not possible to detect this by using simple pure tone audiometry 
(Freilich et al., 1996). Established tests for detection of outer hair cell (OHC) function 
are pure tone audiometry and Otoacoustic emissions (Stavoulaki et a. I, 2001). The 
complete loss of IHC over certain region of basilar membrane is called a dead region. 
Dead regions do not occur in people with normal hearing, except perhaps at very high 
frequencies above the normal audiometric range (Moore,2005-personal 
communication).
1.2 Anatomy
The ear, which houses the peripheral parts of the auditory and vestibular apparatus, is 
descriptively divided into the external, middle and internal ear. The external ear 
consists of the auricle or pinna and the external acoustic meatus at the medial end of 
which lies the tympanic membrane, separating the external ear from the middle ear. 
The middle ear or tympanic cavity (tympanum) is a small space in the temporal bone 
containing the auditory ossicles (malleus, incus & stapes) and air that communicates 
with the nasopharynx by the Eustachian tube. By its medial wall, the middle ear 
adjoins the inner ear, which is composed of the osseous labyrinth, another space 
within the temporal bone, inside which is the membranous labyrinth containing the 
auditory and vestibular nerve receptors.
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1.3 Physiology
The peripheral auditory system is a complex arrangement of various structures 
allowing conduction of acoustic vibrations from the external ear to the inner ear fluids 
and subsequent transduction of sound into electrical messages. Sound is essentially 
vibrations in air of air molecules and has two basic properties namely:- Loudness 
(subjective correlate of intensity) & Pitch (subjective correlate of frequency).
1.4 Dead Regions
Cochlear hearing loss can arise from different causes and it is often associated with 
damage to hair cells within the cochlea. Inner hair cells at certain places along the 
basilar membrane may be non-functional or even missing, thereby leading to no 
transduction of basilar membrane vibration at those places. In addition to the above, 
the auditory neurons associated with certain places may be non-functioning or 
degenerated. This means that the information about basilar membrane vibration at 
those places is not transmitted to the brain. Areas where there are no functioning IHC 
are referred to as dead regions.
1.5 Platinum based chemotherapy drugs
Platinum chemotherapeutic drugs like cisplatin, carboplatin and oxaloplatin have an 
established place in the management of certain malignancies. Their use, however, is 
associated with hearing loss amongst other things (e.g. hair loss, nausea, sub-fertility). 
Ototoxicity is one of the main side effects of cisplatin treatment. Initial signs of 
cisplatin ototoxicity usually become known 3-4 days after drug administration and 
tend to affect the higher frequencies. Even though not life threatening, ototoxicity of 
cisplatin is considered to be a serious side effect and therefore dose limiting (Laurell 
et al, 1987). Several factors have been implicated for higher toxicity; these include 
prior or concomitant radiation, pre-existing hearing loss, decreased renal function, 
concomitant use of other ototoxic drugs, faster infusion rates, very young age, older 
age, larger dose and higher cumulative dose. Carboplatin is less ototoxic than 
cisplatin and its anti-neoplastic activity is equivalent to that of cisplatin. However, 
optimal use of carboplatin is limited by its ototoxic effects (Hussain et al., 2004).
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Macdonald et al, showed in an animal model that there is damage to IHC in the basal 
turn of cochlea, leading to higher frequency hearing loss following use of 
carboplatins, the mechanism for which is unknown (Macdonald et al., 1994). 
Oxaliplatin is a new anticancer chemotherapeutic agent belonging to the platinum 
complex series. On extensively reviewing the literature, there has been only been one 
report of a case of Oxaliplatin induced hearing loss.
1.6 Threshold Equalising Noise (TEN) test
Several researchers have looked into ways of using masking noise to ascertain the 
presence of dead regions (Halpin et al., 1994 & Humes et al., 1984). Pyschophysical 
tuning curves (PTC) are often considered the gold standard for the detection of dead 
regions. However, there are certain factors that can complicate the interpretation of 
the PTC. PTC’s are a valuable useful research tool but are time consuming. Hence 
the search for a simpler test led to development of the threshold equalising noise 
(TEN) test.
Moore (2000) first described a simple way of detecting these dead regions by using a 
hearing test called the Threshold equalizing noise (TEN) test. This involves detection 
of tones in the presence of ipsilateral TEN using the principles of noise audiometry. 
This is a short and simple test available on a CD. A dead region is present when the 
masked threshold is at least 10 dB higher than the absolute threshold and at least 10 
dB above the level of masking noise (Moore et al., 2000)
1.7 Methodology
A prospective longitudinal study was conducted to identify the presence of dead 
regions in the cochlea of patients who have had chemotherapy with platinum based 
drugs using TEN (HL) test. Fifty patients having chemotherapy with platinum 
chemotherapeutic drugs (Cisplatin, Carboplatin & Oxaliplatin) were recruited and 
their hearing assessed by Pure Tone Audiometry and the TEN (HL) test for the 
presence of dead regions before initiation of therapy and then at 1, 6 & 12 months 
post treatment, as it is unknown in the literature about the occurrence of the dead 
regions with regards to the administration of platinum based drugs.
Inclusions:
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■ Age 20-75 years, both male and female patients
■ On chemotherapeutic agents (cisplatin, carboplatin and oxaliplatin) 
Exclusions:
■ Middle or outer ear disease causing conductive hearing loss
■ On other ototoxic drugs (past or present)
■ Congenital hearing loss
■ Patients who do not, or are unable to, consent to the trial
■ Terminally ill patients
1.9 Aim
The primary aim of this thesis is therefore:
To identify dead regions within the cochlea using Threshold Equalising noise (TEN 
HL) test in patients who had chemotherapy with platinum based drugs.
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2.1 Introduction
This chapter provides a brief description of the most basic features of the anatomy of 
the ear. The ear, which houses the peripheral parts of the auditory and vestibular 
apparatus, is descriptively divided into the external, middle and internal ear. The 
external ear consists of the auricle or pinna and the external acoustic meatus, at the 
medial end of which lies the tympanic membrane, separating the external ear from the 
middle ear. The middle ear or tympanic cavity (tympanum) is a small space in the 
temporal bone containing the auditory ossicles {Malleus, incus & stapes) and air that 
communicates with the nasopharynx by the Eustachian tube. By its medial wall, the 
middle ear adjoins the inner ear, which is composed of the osseous labyrinth, another 
space within the temporal bone, inside which is the membranous labyrinth containing 
the auditory and vestibular nerve receptors.
2.2 Components of Ear
The ear is broadly divided into
(i) External ear
(ii) Middle ear cleft
(iii) Inner ear
Ossicles
Pinna
External
Auditory
canal
Cochlea
Eustachian
Tube
Tympanic
membrane
Figure 2.2 Components of the Ear
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2.3 External Ear
The external ear is composed of:
1. External ear canal
2. Pinna (auricle)
3. Tympanic membrane
(i) External Auditory canal
The external ear canal in adults is 2.5cm long with lateral one- third having 
cartilaginous walls and the medial two- thirds bony walls. The continuing curve of the 
deep bony canal results in the tympanic membrane lying at a slant across the bony 
canal with an acute angle between the drum and anterior canal wall.
(ii) Pinna (auricle)
The body of the auricle is made up of elastic fibrocartilage and is a continuous sheet 
except for a narrow gap between the tragus and anterior crus of helix, where it is 
replaced by dense fibrous tissue band. Both pinna and external auditory canal, from 
anatomical aspect, provide protections of the tympanic membrane (and the middle ear 
beyond) from direct injury, act as a directional amplifier of sound and provide 
important cues for sound localization. Pinna and external ear canal are now 
recognized as significant components and are far from being vestigial in function.
(iii) Tympanic membrane
The tympanic membrane is slightly oval in shape and is approximately 9-10 mm in its 
maximum diameter from postero superior to anterosuperior. It is like a curved cone 
with a single layer of squamous epithelium on canal side and a single mucosal layer 
on the middle ear side with an intervening layer composed of fibrous tissue. This 
layer is composed of collagen fibres aligned in a radial and circular fashion.
Tympanic membrane vibrates in response to sound energy and transmits the resulting 
mechanical vibrations to the structures of the middle ear.
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Malleus Incus
Mastoid air 
cells
Stapes
Tympanic
membrane
Eustachian
tube
Figure 2.4 Middle ear Cleft
2.4 Anatomy of middle ear cleft
The middle ear cleft consists of a centrally filled space - the tympanum, its connection 
to the pharynx (Eustachian tube) and its extension to the neighbouring region of 
temporal bone.
The different parts of the middle ear cavity are: -
1. Eustachian tube
2. Tympanic (middle ear) cavity
3. Aditus ad antrum
4. Mastoid antrum
5. Mastoid air cells
6. Ossicles (malleus, incus & stapes)
The ossicles (malleus, incus & stapes) form a semi -  rigid bony chain for conducting 
sound and their primary function is to amplify sound and act as an impedance- 
matching device, to compensate for the difference in impedance between air and the 
fluids of the inner ear.
7. Two muscles namely Tensor tympani and Stapedius
Both the tensor tympani and the stapedius are the smallest striated muscles in the 
body and are enclosed within the middle ear cavity. The tensor tympani muscle 
attaches to the medial aspect on the upper part of the handle of malleus and the
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stapedius muscle emerges from the pyramidal eminence to attach to the upper part of 
the posterior crus of the stapes. They play an active role in the acoustic reflex, in 
addition to supporting and stiffening the ossicular chain. Contraction of both muscles 
is primarily activated by acoustic stimulation of 70-90 dB above threshold and thus, 
they protect the inner ear from excessive and potentially damaging loud noise 
exposure.
2.5 Inner ear
The inner ear lies within the petrous part of the temporal and consists of bony 
labyrinth enclosing a membraneous labyrinth. Perilymph lines the space between 
bony and membraneous labyrinth while endolymph fills the membraneous labyrinth 
and contains sensory cells of hearing and balance.
The inner ear is divided into the cochlea, which is responsible for transduction of 
sound into neural activity and the vestibular apparatus, which is responsible for 
assisting in balance.
Scala
Vestibuli
Reissner’s
membrane
Hair cells
(IHC
&OHC)
(BM)
Basilar
membrane
Cochlear
JDuct
Tectorial
membrane
(TM)
Cochlear
Scala
tympani
nerve
Figure 2.5 Inner Ear
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(i) Cochlea
The bony cochlea has a coiled shell like appearance and houses a spiral structure, a 
part bone, a part membrane called the cochlear duct or scala media. This contains 
endolymph and sensory cells of hearing.
(a) Cochlear duct
It is triangular in section and spirals approximately two and half turns from base to 
apex. The human cochlear duct has a length of approximately 35mm. The duct has a 
flat floor called the spiral lamina, a sidewall that is mainly stria vascularis and a 
sloping diagonal roof called Reissner’s membrane. Stria vascularis is the upper end of 
spiral ligament (thickened outer periosteum of the cochlear duct) comprised of 
numerous capillaries and blood vessels and involved in production of endolymph. The 
spiral lamina of the cochlea runs around a central bony core called the modiolus. At 
the apex of the modiolus the spiral lamina tapers off into the fluid filled spaces of the 
apex of cochlea. The spiral lamina has a bony portion -  the bony spiral lamina 
attached to the modiolus - and a membranous portion or basilar membrane, which 
extends from the edge of bony spiral lamina to the outer wall of the labyrinth.
(b) Organ of Corti
This is a band like structure situated on the basilar membrane and contains auditory 
hair cells. These sensory cells have hair like stereocilia projecting from their upper, 
endolymphatic surfaces and are called hair cells. There are two types of auditory hair 
cells, the inner hair cells (IHC) and outer hair cells (OHC). The IHC lies closer to the 
modiolus than the OHC and has a rounded flask like shape. It is surrounded by 
supporting cells and has about 10 separate afferent auditory nerve fibres that make 
synaptic connection with its basal end. There are approximately 3,500 IHCs and 
12,000 OHCs in healthy human cochlea. Between the IHCs and OHCs is a triangular 
space called the tunnel of Corti. The roof of this formed by the arch of processes of 
the inner and outer hair pillar cells. Each OHC is cylindrical in shape and is supported 
at its lower pole by the cup like processes of Deiters’ cells.
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BM: Basilar membrane 
OHC: Outer hair cells 
IHC: Inner hair cells 
VIII: Cochlear nerve 
TM: Tectorial membrane 
M: Modiolus
Figure 2.5 (i) b Organ of Corti
The body of OHC is therefore surrounded by a space that is filled with a fluid called 
cortilymph, which has probably the same composition as perilymph. The OHC only 
contribute a little to the afferent innervation arising from cochlea but they have a good 
efferent supply coming from various tunnel crossing fibres that in turn derive from the 
olivocochlear bundle. There are approximately 12,000 OHCs in each organ of corti. 
The apical surfaces of the OHC and IHC have stereocilia projecting from them into 
the endolymph. Each of the stereocilia in a bundle on one hair cell is linked by very 
fine links to the adjacent stereocilia (see section 3.6). The tips of shorter stereocilia 
also have links to the adjacent taller stereocilia and it is these links that are thought to 
be responsible for the opening of ionic channels during auditory stimulation.
The tectorial membrane arises from a lip or limbus on the edge of bony spiral lamina. 
The membrane, which is a fibrogelatinous structure, spreads outwards across the 
organ of corti and in life, attaches to the supporting cells, which lie on the outer side 
of the OHCs. The tips of the longest stereocilia of the OHC insert a little way into the 
tectorial membrane (Wright, 1997).
2.5 Conclusion
The basic knowledge of the relevant clinical anatomy of the ear is essential in the 
context of this thesis, as it helps in understanding the effects of platinum based 
chemotherapeutic drugs on the inner ear.
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3.1 Introduction
The peripheral auditory system is a complex arrangement of various structures 
allowing acoustic energy, in the form of sound waves, to be channeled into the ear 
canal by the pinna. Sound waves strike the tympanic membrane, causing it to vibrate 
like a drum, and changing it into mechanical energy. The malleus, which is attached 
to the tympanic membrane, starts the ossicles into motion. (The middle ear 
components mechanically amplify sound). The stapes moves in and out of the oval 
window of the cochlea creating a fluid motion. The fluid movement within the 
cochlea causes membranes in the Organ of Corti to shear against the hair cells. This 
creates an electrical signal, which is sent via the Auditory Nerve to the brain, where 
sound is interpreted.
This chapter explains this process in more detail.
3.2 Physiology of sound transduction
Sound is essentially vibrations in air of air molecules and a sound wave has two basic 
properties namely: -
1. Loudness -  subjective correlate of intensity
2. Pitch -  subjective correlate of frequency
The purpose of the Cochlea is to transduce vibrations into neural activity. These 
vibrations displace the cochlear fluids, producing a wave of displacement that travels 
along the Basilar membrane, which reaches, from the base to the apex of the cochlea, 
which increases in amplitude before decreasing fairly abruptly (Pickles, 2005; Moore, 
2007). Response to a sound of a given frequency is determined by the mechanical 
properties of the basement membrane, being narrow and stiff at the basal end and 
responding preferentially to high-frequency sounds. Conversely, low-frequency 
sounds are better appreciated at the apex, where it is wider and more flexible (Pickles, 
2005).
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Distance from stapes, mm
Figure 3.2 I l lu s tr a t io n  of travelling wave (BM displacement/distance from stapes). The 
solid lines illustrate the instantaneous displacement of the BM at four successive 
instants in time (labelled 1-4). The pattern moves from left to right, increasing 
gradually with distance and reducing rapidly after the point o f peak displacement 
(Moore, 2007, p .12)
3.3 Tonotopic distribution & basilar membrane
The basilar membrane (BM) is tonotopically structured with each point along its 
length responding with maximum resonance to a certain sound frequency termed the 
characteristic frequency (CF) (Pickles, 2005). The deformation o f the basilar 
membrane is a traveling wave. When motion of the stapes establishes a sound wave in 
the fluid of the inner ear, each small region of the basilar membrane deflects 
in response to this pressure with a time delay that depends upon its own mechanical 
properties. The wave then diminishes rapidly in both amplitude and velocity as it 
continues to move toward the apex. The area of basilar membrane nearest to the oval 
window resonates best to sounds of high frequency whereas low frequency sounds 
resonate the apex better. This is due to the mechanical properties of the basilar 
membrane as it is narrow and stiffer at the base than it is at apex, thereby leading to
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decrease in its resonance frequency as sound waves travel away from oval window 
towards the apex.
25 Hz
50 Hz
400 Hz
1 600 Hz
10 20 30
Distance from stapes, mm
Figure 3.3 Demonstration of the envelope of patterns of vibration along the BM for 
low-frequency sounds (Moore, 2007, p. 14)
3.4 The Role of Outer Hair cells (OHC)
Outer hair cells reside within the Organ of Corti (figure 2.5 b) supported by Deiters’ 
cells and Hensen’s cells and are susceptible to damage by ototoxic drugs, noise 
exposure, metabolic changes and infection. The stereocillia of OHC’s are in contact 
with the tectorial membrane, which lies above them throughout the length of the 
cochlea. The depolarization of OHCs, (see section 3.6) resulting from movement of 
their respective stereocilia, results in their expansion and contraction, influencing the 
response of the BM to sound (Pickles, 2005).
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Figure 3.4 Components of the Inner ear
The OHC’s play a role in the active mechanism of the cochlea by changing their own 
stiffness and length in response to the vibrations of the sound wave. This activity of 
the outer hair cells enhances the responses to weak sounds (increasing the amplitude 
of vibration) and sharpens the tuning on the basilar membrane, thereby increasing the 
frequency selectivity of the auditory system i.e. its ability to separate out the different 
frequencies that are present in complex sounds such as speech and music. The 
amplified vibrations are then detected by the inner hair cells (IHC), which form a 
single row running along the length of the basilar membrane. In response to the 
vibrations on the basilar membrane, IHC’s generate electrical signals and release 
neurotransmitter and this in turn leads to neural activity in the auditory nerve.
3.5 The Role of Inner Hair Cells
There are 3,500 Inner hair cells (IHCs) in a healthy human cochlea and they have a 
large synaptic contact with the afferent nerve fibres of the auditory nerve. They are 
the true sensory receptors in the cochlea and their primary role is to convey sound 
information through a process of transduction in response to basilar membrane 
vibrations.
Cochlear hearing loss is often associated with damage to the hair cells thereby leading 
raised hearing thresholds. OHC’s injury causes impairment of the active mechanism
Cochlear
Duct
Tectorial
membrane
Basilar
membrane
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in the cochlea, which results in reduced basilar membrane. Hence the sound level 
must be larger than normal to give a just detectable amount of vibration. On the other 
hand, IHC damage can lead to a less efficient stimulation of the auditory nerve.
3.6 Molecular Physiology
Hair cells (inner & outer) have apical stereocilia made up of actin filament inserted 
into the cuticular plate, although the stereocilia of the IHC do not touch the tectorial 
membrane. These are aligned in four rows with the tallest one being at the most 
lateral side of the hair cell. Stereocilia are linked with each other at their tips which 
project into the endolymph (high concentration of potassium ions) while the body of 
the hair cells is bathed in Perilymph (high in sodium ions and low in potassium ions). 
A strong electrochemical gradient exists between the endolymph and intracellular 
space. Sound waves cause deflection of the stereocilia towards the tallest cillium, 
resulting in the opening of the ion channels at the tip links. This results in the inflow 
of potassium ions intracellularly causing depolarization of cell body, opening of 
voltage gated calcium channels and release of the neurotransmitters. IHC release 
Glutamate into synaptic spaces causing activation of afferent nerve fibres. OHC, on 
the other hand, following depolarization exhibit electromotility and thus contribute to 
shaping the mechanical excitation of the IHC (Pickles, 1997)
Ion channel 
& tip links
Stereocilia
Tip links
Hair cell
Figure 3.6 Molecular Physiology
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Whilst OHCs are more susceptible to damage than IHCs it is possible, though rare, 
for there to be intact OHCs but damaged IHCs. Consequently sharp tuning 
contributed by OHCs is preserved. However, damage to IHCs results in increased 
absolute thresholds. Increased BM vibration is required to produce ‘threshold’ 
amounts of neural activity for their respective CFs. Complete loss of (or significantly 
damaged) IHCs results in distorted perception of sound frequencies corresponding to 
the CFs of those IHCs. Generally, with severe hearing loss, there is an absence of 
both OHCs and IHCs, resulting in a combination of the above effects (Moore, 2007)
3.8 Conclusion
This chapter provides a basic outline of the physiology of hearing process and will be 
helpful in the understanding of pathophysiological effects of the platinum based 
chemotherapeutic drugs on the inner ear in the following chapter.
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4.1 Introduction
Medicines procured from herbs, soil or animals have been used for humans since the 
dawn of civilization. Drug induced hearing loss was first reported about 1000 years 
ago by Abu Ali al-Husayn ibn Abd-Allah ibn Sina, who is better known as Avicenna 
and the author of ‘Canons on Medicine’. He stated in his book that the use of mercury 
vapours to kill head lice led to hearing loss (Schacht, 2006). The first well 
documented drugs associated with hearing loss were salicylate and penicillin 
(Stephens, 1982).
The modem era of chemotherapy came with the discovery and synthesis of Salvarsan, 
an arsenical drug for treatment of syphilis, by Paul Ehrlich. A number of cases of 
cochlear nerve deafness emerged following the introduction of Salvarsan and it has 
the dubious honour of being labelled as the first modem drug to be linked with 
undesirable effects on the ear (Schacht and Hawkins, 2006).
Cisplatin (cis-diamminedichloro-platinum) was first synthesized in 1845 but it was 
only after 125 years that its anti-neoplastic potential was discovered and first clinical 
trials published. However, with the celebrated efficacy of cisplatin against various 
tumours came many side effects with ototoxicity being one of them. The primary 
targets of cisplatin ototoxicity are the outer and inner cells and the stria vascularis. 
Carboplatin, its sister drug, seems to be less ototoxic but has a predilection for the 
inner hair cells. The reported incidence of cisplatin ototoxicity in the literature varies 
from 9% to 91% (Ryback et al., 1981).
Ototoxicity is defined as the tendency of certain therapeutic agents and other chemical 
substances to cause functional impairment and cellular degeneration of the tissues of 
the inner ear and especially of the end organs and neurons of the cochlear and 
vestibular divisions of the VIII cranial nerve. Ototoxicity has been divided in five 
grades by the National Cancer Institute (Williams et al., 1995). These are as follows: - 
Grade 1: None or no change in hearing level 
Grade 2 : Asymptomatic, hearing loss on audiometry only 
Grade 3: Tinnitus & asymptomatic hearing loss
Grade 4: Hearing loss interfering with function, correctable with hearing aid 
Grade 5: Deafness not correctable
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4.2 Platinum Based chemotherapy drugs
Platinum-based natural metal derivatives were found to be useful for cancer 
treatments around 150 years ago with the synthesis of cisplatin. However, their 
clinical use did not commence until 30 years ago. Platinum-based chemotherapy 
agents work by cross-linking subunits of DNA. These agents act during any part of 
the cell cycle and help in treating cancer by impairing DNA synthesis, transcription, 
and function. The platinum based chemotherapeutic drugs include:
1. Cisplatin
2. Carboplatin
3. Oxaliplatin
4.2 (i) Cisplatin
(a) Introduction
Cis-platinum (Cis-diamminedichloro platinum II) is a metal co-ordination complex 
whose chemical structure is unique among current chemotherapeutic agents (Ryback 
et al, 1981). Two main side effects noted are tinnitus and hearing loss, which can 
occur simultaneously or separately. Hearing loss is often permanent, or may be 
partially reversible although complete recovery has been reported (Aguilar-Markulis 
et al, 1981).
(b) Pathophysiology
Morphological studies have been carried out to look at the damage caused by use of 
cisplatin on the inner ear of guinea pigs (Fleischman et a l, 1975) as well as rhesus 
monkeys and humans (Wright & Schaefer 1982). The biochemical mechanism of 
hearing loss caused by cisplatin is still a mystery (Blakely et a l, 1993). However, the 
most notable morphological alteration as a result of cisplatin administration is the 
destruction and degeneration of the outer hair cells of organ of corti as well as the 
inner hair cells. Komune (1981) and Boheim & Ekkehard (1985) reported atrophy of 
the stria vascularis and collapse of Reissner’s membrane as result of cisplatin use. 
First, the outer hair cells near the base of the cochlea are affected and then the damage 
progresses apically and to inner hair cells. Initial signs of cisplatin ototoxicity usually 
become known 3-4 days after drug administration and tend to affect the higher
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frequencies. Even though not life threatening, ototoxicity of cisplatin is considered to 
be a serious side effect and therefore dose limiting (Laurell et al., 1987). Cisplatin 
induced hearing loss is usually bilateral and symmetrical but asymmetry can exist 
(Vermorken et al., 1983).
There is a wide individual variability in the dose needed to produce an ototoxic effect. 
A simple dose to effect relationship does not seem to exist for cisplatin ototoxicity. 
The incidence of hearing loss is markedly high in those receiving single high dose 
injections, which may suggest a correlation between ototoxicity and peak plasma 
concentrations (Reddell et al., 1982). Cisplatin binds extensively to albumin and other 
serum proteins and the active cytotoxic component of cisplatin is in the unbound 
portion.
(c) Review of Literature
Some reports in the literature have indicated that there may be risk factors associated 
with cisplatin ototoxicity. The reported incidence of cisplatin ototoxicity in literature 
varies from 9 to 91%. On reviewing the literature, there appears to be no clear 
consensus as to whether age or pre-existing hearing loss are risk factors for cisplatin 
induced hearing loss (Blakley et al., 1994). A pre-existing hearing loss does not 
increase the ototoxic effects of cisplatin (Piel et al., 1974). It has been suggested that 
hearing will not worsen even if chemotherapy is continued. This has been labelled as 
a plateau effect (Kopelman et al., 1988). Laurel & Borg (1988) reported that neither 
age nor pre-existing hearing loss is a risk factor for cisplatin ototoxicity. Concurrent 
or adjuvant administration of cisplatin along with radiotherapy can potentiate hearing 
loss especially in the high frequencies (Low et al., 2006). Ototoxicity by cisplatin can 
also occur in a cumulative manner after several low dose injections (Aguilar-Markulis 
et al., 1981).
Blakley (1994) in their study looked at the risk factors for ototoxicity due to cisplatin. 
They assessed the hearing of a cohort of 42 patients with head and neck cancer 
undergoing chemotherapy with cisplatin. According to them, cisplatin binds to 
albumin and the active form remains in an unbound state. They hypothesized that 
protein-binding effects are responsible for greater toxicity when albumin levels are 
low. In addition, when the oxygen carrying capacity of the blood is low, the inner ear 
is more susceptible to damage. This may be directly due to chemical oxidation -
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reduction reactions. However, the data from their study did not pinpoint any specific 
mechanism for cisplatin- induced ototoxicity. It seems reasonable to state that any 
measures that optimise tissue oxygenation may decrease the ototoxic effects of 
cisplatin.
Skinner (1990) reviewed 22 children who received cisplatin for solid tumours and 
assessed their hearing. They concluded that cisplatin usage led to high frequency 
hearing loss with significant hearing loss being noted in all patients but one. It seems 
that the severity of hearing loss in individual children tended to increase with higher 
cumulative dose of cisplatin with high frequency loss appearing to stabilise after 
600mg/m2 body surface area.
Rademaker-Lakhai (2006) looked at the auditory toxicity associated with dose- and 
schedule- intensive cisplatin/gemcitabine chemotherapy in non-small-cell lung 
carcinoma patients. A total of 328 audiograms were analysed with a majority of 
patients demonstrating, a decrease in hearing thresholds at dosages above 60 mg/m2 
body surface area of cisplatin at the higher frequencies. Pure tone audiometry at 1,2, 
and 4 kHz showed a mean hearing loss of 19 dB after cisplatin administration at 
dosages above 90 mg/m2 body surface area. Threshold shifts at 8 and 12.5 kHz after 
cisplatin administration were experienced at dosages above 60 mg/m body surface 
area. They concluded that hearing loss after cisplatin therapy occurs mainly at high 
frequencies and at dosages higher than 60 mg/m2 body surface area. It is more 
pronounced when cisplatin is given once every 2 weeks. Pigmentation of the iris may 
influence susceptibility of an individual to cisplatin ototoxicity and cause high 
frequency sensorineural hearing loss but the mechanism remains unclear (Todd et al., 
1995).
4.2 (ii) Carboplatin
(a) Introduction
Carboplatin [ cis -diamine (1,1-cylcobutanedicarboxylate) platinum (II)] is used as an 
alternative drug in oncology for treating small cell lung cancer, ovarian cancer, and 
carcinomas of the head and neck among many other types of cancer. It was introduced 
in the late 1980s and has since gained popularity in clinical treatment due to its vastly 
reduced side effects compared to its parent compound cisplatin. The antitumour
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action of carboplatin is mediated by alkylation o f DNA, which causes the killing of 
the cancerous cells (Los et a l , 1993)
(b) Pathophysiology
Carboplatin is less ototoxic than cisplatin and its anti-neoplastic activity is equivalent 
to that of cisplatin. Carboplatin causes ototoxicity by a direct effect on inner hair cells 
at the base of the cochlea. Oxidative stress to inner hair cells and cochlea could be 
direct consequence of carboplatin-induced ototoxicity. Ototoxicity is dose dependent 
and cumulative and rarely due to neural damage and tinnitus usually is the first 
symptom (Hussain et al., 2004).
(c) Review of Literature
Carboplatin ototoxicity has been well reported in the literature. Carboplatin may 
cause subclinical or overt ototoxicity in 15% and 1% of the patients, respectively 
(Canetta et al., 1987). Rosell (1999) detected 3% of any grade and less than 1% of 
severe (grade 3) ototoxicity in 306 patients with non-small-cell lung cancer patients 
receiving carboplatin-paclitaxel combination in their study. Parsons (1998) observed 
ototoxicity in 82% of children treated for neuroblastoma where carboplatin was used 
as part of the treatment regimen.
Du Bois (2003) reported 0.3% grade 3 ototoxicity without any grade 4 ototoxicity, in 
patients with ovarian cancer treated with paclitaxel-carboplatin combination regimen.
4.2 (iii) Oxaliplatin
Oxaliplatin is a new anticancer chemotherapeutic agent belonging to the platinum 
complex series. Two platinum derivatives, cisplatin and carboplatin, were until 
recently the only platinum compounds used clinically. It exerts its anti-tumour effects 
by platinum-adduct formation, binding to cellular proteins and possibly interfering 
with RNA synthesis as well.
These products have major activity in a variety of solid tumors, such as testicular, 
ovarian, bladder and lung carcinomas. However, their use is limited by severe toxicity 
including nephrotoxicity, severe gastrointestinal intolerance (with nausea and 
vomiting), and myelosuppression.
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In order to improve the efficacy, as well as to circumvent acquired resistance and/or 
decrease toxicity, the search for new chemical entities led to the discovery of the 
diaminocyclohexane (DACH) platinum family in the 1970s. Oxaliplatin (trans-1 
DACH oxalatoplatinum or L-OHP) was described in 1976 in Japan by Pr. Kidani, and 
is the first DACH-member to reach the market (Galanski et al.9 2004).
On reviewing the literature (search terms: Oxaliplatin AND / OR hearing loss: 1966 
to date), there has been only one report of a case of oxaliplatin induced hearing loss. 
Malhotra (2010) reported unilateral hearing loss in a 70-year-old woman who was 
undergoing postoperative chemotherapy for rectal adenocarcinoma and had developed 
hearing loss following a single infusion of Oxaliplatin, which persisted and never 
recovered.
4.3 Preventing and monitoring ototoxicity
Ototoxicity is the primary dose limiting effect of cisplatin and carboplatin 
(to a lesser extent) and can be influenced by various factors such as drug 
administration method, dosage per treatment and accumulated dosage. To date, 
attempts to reduce the side effects by developing equally potent platinum analogs has 
proved futile. Some success however has been achieved by co-treatment with 
protective agents. Most of these agents are sulphur or sulfhydryl containing 
compounds (thio compounds) known as antioxidants and potent heavy metal 
chelators. They provide protection against cisplatin ototoxicity in the following 
ways:-
1 Direct interaction between cisplatin and thio moiety
2 Preventing platinum from interfering with superoxide dismutase
3 Displacing platinum from its site of toxic action
4 Scavenging cisplatin induced free radicals (Smoorenburg et al., 1999)
D- methionine, sulphur containing nucleophile and antioxidant, may protect against 
cisplatin-induced ototoxicity by chelating the platinum, reversing the cellular 
platinum -thiol complexes, protecting the essential aminoacid L-methionine or simply 
functioning as an antioxidant. It does appear to have a fairly generalised protective 
effect not only against ototoxicity but also against nephrotoxicity (Campbell et al., 
1999).
Monitoring the ototoxic effects of cisplatin has also been a topic of discussion.
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Fausti (1993) suggested that an effective hearing monitoring protocol should provide 
the earliest possible detection of hearing loss. The proposed recommendations are 
conventional audiometry (250Hz to 8000Hz), high frequency audiometry and 
otoacoustic emissions(OAE). However, the basic audiological assessment is still 
limited to conventional audiometry. High frequency audiometry, on the other hand, 
can be employed to detect ototoxic changes caused by cisplatin above 8000 Hz, which 
corresponds to early cochlear insults. It clearly detects pre-clinical ototoxicity with 
greater sensitivity than conventional audiometry. (Durant et al, 2009)
Knight (2007) evaluated the feasibility of extended high frequency audiometry (EHF; 
9 to 16kHz) and distortion product otoacoustic emission (DPOAEs) as a mode for 
monitoring ototoxicity in patients having platinum based chemotherapy by measuring 
hearing thresholds using conventional audiometry (0.5 to 8000 kHz) in 32 patients 
and EHF and DPOAEs in 17 patients. Their results showed that EHF and DPOAEs 
identified ototoxic changes earlier when compared with conventional audiometry. 
Coupland (1991) investigated the usefulness of broadband clicks and derived auditory 
brainstem evoked response audiometry (ABR) in investigation of early cisplatin 
ototoxicity by monitoring progressive hearing loss in 18 children undergoing 
chemotherapy over a two-year period. They concluded that derived ABRs were found 
to be more sensitive than broadband click ABR in detecting early high-frequency 
hearing loss.
4.4 Conclusion
Platinum based drugs are invaluable for the treatment of many types of cancer 
including head and neck but do have serious side effects, of which, hearing loss is 
one. This can be very debilitating for patients. It is of paramount importance that the 
ototoxicity occurring as result of these agents is effectively monitored and prevented.
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5.1 Introduction
Sounds entering the ear lead to vibrations of the basilar membrane within the cochlea 
with high frequencies producing maximal vibration at the base and low frequencies 
towards the apex of the basilar membrane. The frequency that leads to the maximal 
vibration at a given place on the basilar membrane is called the characteristic 
frequency (CF) for that place. Cochlear hearing loss is often associated with damage 
to the hair cells thereby leading raised hearing thresholds. OHC’s injury causes 
impairment of the active mechanism in the cochlea, which results in reduced basilar 
membrane. Hence the sound level must be larger than normal to give a just detectable 
amount of vibration. On the other hand, IHC damage can lead to a less efficient 
stimulation of the auditory nerve. IHC at certain places along the basilar membrane 
may be completely non-functioning and the auditory neurons making the connection 
may be non-functioning. Places with non-functioning IHC’s and /or neurons have 
been referred to as ‘dead regions’. A high frequency tone presentation may be 
detected a region closer to the low frequency (apical end) if it produces sufficient 
basilar membrane vibration and similarly a low frequency tone may be detected via 
neurons that are tuned to detect high frequency tone. This in turn leads to the true 
hearing loss at a given frequency being greater when compared with the audiometric 
threshold at that frequency.
5.2 Dead Regions
(i) Definition
In regions of the cochlea where Inner Hair Cells (IHC) or their associated neurones 
are completely non-functional, the transduction process cannot occur; there is no 
conversion of basilar membrane (BM) vibration into action potentials. Consequently 
information from BM vibration within that region cannot be passed to the brain; the 
hearing loss in such regions is effectively infinite. This phenomenon is known as a 
‘Cochlear Dead Region’ (Moore, 2004)
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(ii) Review of literature
The extent of a dead region (DR) has previously been defined according to location 
or distance along the Basilar Membrane, which was non-functioning, for example 
extending from 0-12mm for a basal dead region (Moore, 2004 ; Moore, 2001). As 
the cochlea is known to demonstrate frequency-place specificity, a dead region may 
also be defined by the CF normally associated with that region e.g. extending from 
4000 to 1000 Hz (Moore, 2002). When a dead region is present, an audiogram can 
give misleading information on the extent of the hearing loss, for a tone whose 
frequency falls in the dead region. The true hearing loss in a dead region is infinite, 
but an audiogram may only indicate a moderate hearing loss if the frequency of the 
tone lies close to the boundary of the dead region (Moore, 2004). Halpin (1994) 
described two patients with low frequency hearing loss on their audiograms. 
However, on postmortem examination, one had no surviving organ of corti at apical 
region whereas the other person had normal organ of Corti. Moore (2000) stated that 
steep sloping audiograms (high frequency hearing loss) are usually associated with 
dead regions but dead regions can also be linked to a shallow sloping audiogram.
(iii) Clinical signs
The following table illustrates the clinical signs of dead regions.
Clinical signs o f a DR Source
Audiogram slope and severity: Moore (2004)
(i) Hearing losses o f  >90dB at Aazh & Moore (2007)
high frequencies or 75- Vinay & Moore (2007)
80dB at low frequencies
(ii) Hearing losses o f  40-50dB
at low frequencies with
near-normal hearing at
medium and high
frequencies (perhaps
indicative o f a low-
frequency DR)
(iii) Hearing losses >50dB at
low frequencies with
somewhat less hearing loss
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at higher frequencies 
(perhaps indicative o f  a 
low-frequency DR)
And/or:
Hearing loss increasing rapidly (more 
than 50dB/octave) with increasing 
frequency (perhaps indicative o f  a high- 
frequency DR)
Subjective reports from the patient during 
PTA that the tones sound noise-like rather 
than tone like. This often occurs where the 
pure tone falls well within a DR. Reports o f  
noise-like tones may also occur where there 
is no DR.
Moore (2004)
Huss and Moore (2005) 
Munro (2007)
Lack o f  benefit from previously fitted 
hearing aids
Moore (2004)
Table 5.2(iii): Clinical signs of Dead Regions
(iv) Methods of detection
Whilst BM vibration information arising within a dead region itself is not 
transmitted to the brain, a tone of frequency falling within a dead region may still 
be detected. An apical or basal spread of the vibration pattern to adjacent 
functioning IHCs and neurons of a different CF will result provided the sound is 
of a sufficient intensity (Moore and Alcantara, 2001). Such detection of a sound 
is referred to as ‘off-frequency’ or ‘off-place’ listening (Moore, 2004). The tests 
for the detection of dead regions are based upon the occurrence of off-place 
listening. Many researchers have used masking techniques to establish the 
presence of dead regions and to approximate their boundaries (Moore and 
Alcantara, 2001; Summers et al., 2003; Sek et al., 2005). Various tests, which 
have been used to detect dead regions, include
(i) Traditional Psychophysical Tuning Curves (PTCs)
(ii) Threshold equalizing noise test (TEN)
(iii) Fast Psychophysical Tuning Curves (PTCs)
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5.3 Threshold Equalising noise (TEN) test
(i) Review of Literature
Moore (2000) developed a test using an alternative masking technique for detection of 
dead regions, which avoids the problems associated with PTC (Psychophysical tuning 
curve). The long test duration of PTCs has also been shortened considerably to 
roughly twice as long as measurement of a single audiogram; masked thresholds of 
sinusoids are measured for only of the standard audiometric frequencies in the 
presence of Threshold Equalising Noise (TEN Test) (Moore et al., 2000; Moore,
2002; Moore, 2004; Kluk and Moore, 2006).
A two-channel audiometer is required to mix and independently adjust the levels of 
the sinusoid and TEN, which is sourced from a compact disc (CD) upon which it is 
recorded, and presented to the same ear (Moore, 2002). TEN test is spectrally shaped 
so that masked thresholds (dB SPL) for normally hearing subjects should be equal for 
sinusoids between 250-10,000 Hz (Moore et al., 2000).
The test involves measuring the thresholds for detecting a pure tone presented in a 
background noise called threshold equalising noise. Initially the noise was 
synthesized in such a way that the threshold for detecting a tone in the noise, specified 
in dB SPL, was approximately the same for all tone frequencies in the range 250Hz to 
10Hz, for people with normal hearing. However, a problem with this original version 
of TEN test for the clinician was the fact that he had to measure absolute threshold 
(audiometric threshold) twice, once using the tones generated by the audiometer with 
level specified in dB HL and once using the tones from TEN test CD with level 
specified in dB SPL. In order to overcome this, a new version was designed in which 
the noise gave equal masked thresholds in dB HL for all frequencies from 500 to 
4000Hz for normally hearing individuals. As all the calibrations are in dB HL, 
absolute thresholds can be measured either using the tones generated by the 
audiometer or using the test tones from the CD, the results would be similar.
(ii) Rationale behind TEN test
The rationale behind the TEN test involves measurement of threshold for detecting a 
pure tone noise in the background of a masking noise. A pure tone signal, when 
presented to the ear, is detected by fully functioning inner hair cells on the basilar
42
membrane frequency leading to a response. The introduction of a background noise 
does not lead alteration of the thresholds on masking as there are fully functioning 
inner hair cells on the basilar membrane. However on the other hand, when there are 
no functioning hair cells on the basilar membrane, a pure tone signal falling in the 
area o f the dead region leads to less then sufficient basilar membrane vibration. This 
is due the fact this pure tone signal is now being picked by remote areas on the basilar 
membrane where there are some functioning IHC’s. The amount of vibration 
produced as a result at this remote region will be less than in the dead region and 
thereby the masking the noise will be very effective in masking it as well as any off 
peak frequency listening and hence more accurate thresholds.
No dead region
Traveling wave 
envelope tor noise
Traveling wave envelope 
tor pure tone
Distance from stapes
Maximum stimulation of 
inner hair cells in th« region
Distance from stapes
Dead
region
Dead region
Travelling wave 
envelope for noise
Travelling wave envelope 
for pure tone
Stimulation of IHCs can only occur at 
IHCs adjacent to the dead region 
Vibration amplitude is lower at adjacent 
region so puretone is masked by n o se
Figure 5.3 (ii) Travelling wave & dead region (Meredith, 2010- personal communication)
Additionally, TEN used with the dB (HL) version has a restricted bandwidth (now 
354-6,500 Hz, as opposed to the 250-10,000 Hz range of the original TEN), 
producing almost equal masked thresholds between 250 Hz -4 KHz. This enables the 
masker level to be increased whilst avoiding the complications of distortion,
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excessive loudness and possible noise-induced damage to hearing (Moore et al., 
2004). The TEN (HL) test is therefore more efficient and faster than its predecessor. 
As with the original TEN test, frequencies falling within a dead region are identified 
by masked thresholds that exceed the absolute threshold by at least 10 dB and also a 
minimum 10 dB above the level/ERB of TEN used (Moore et al., 2004).
Whilst in clinical audiology it is standard practice to measure thresholds within 5 dB, 
Moore (2004) suggests a step size of 5 or 10 dB to approximate the level of masked 
threshold, then a smaller step size of 2 dB to determine it more precisely. He also 
acknowledges the limited accuracy of both versions of the TEN test; the test 
frequencies used on the CD necessary to perform the test are spaced at one-half 
octave intervals, inherently limiting precision of the test in determining fe (Dead 
region edge frequency)
Cairns (2007) investigated short-term test-retest repeatability of the TEN (HL) test 
(between 0.5-4kHz) for 15 teenagers with long-standing severe-to-profound 
sensorineural hearing loss (SNHL), and 20 adults with moderate-to-severe SNHL, by 
repeating the TEN (HL) test within five days using the same equipment. They 
concluded that less than 5% of ears tested for both groups changed category at 
individual frequencies, with the exception of 1.5 and 4 kHz. Most ears that changed 
category only just met dead region criteria. Markessis (2006) reviewed 24 subjects 
with normal hearing and 35 patients with steeply sloping high-frequency for the effect 
of high-pass filtering on the TEN-test results and the loudness of the TEN. They used 
the standard TEN (TENs), and TEN high-pass filtered at 0.5 kHz (TEN0.5) or 1 kHz 
(TEN1). The TEN1 was found to be the most comfortable noise by 68% of the 
hearing-impaired subjects and concluded that high-pass filtering would allow testing 
at higher TEN levels for patients with steeply sloping hearing loss.
(iii) Limitations
The original TEN test measured levels in dB (SPL) resulting in clinicians measuring 
thresholds twice, once in dB (HL) then in dB (SPL). Actual levels of sound for both 
the masker and sinusoid presented to the test subject were not as indicated by the 
audiometer; the masker being 1 OdB(SPL) lower whilst the test tone (also sourced 
from the CD) was 10dB(SPL) higher (Moore, 2002). There was difficulty achieving
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valid results for those with severe or profound hearing loss (Moore et a l , 2003). 
Moore (2004) have attributed this to three main reasons:
(i) Insufficient levels of masking to raise the masked threshold by 1 OdB or more 
above the absolute threshold due to excessive loudness (thus inconclusive results 
obtained).
(ii) Avoiding potentially damaging noise levels.
(iii) Limitations of the audiometer.
Moore (2004) argued that structural abnormalities within the test cochlea might result 
in the TEN test criteria being met due to a resultant absence of residual frequency 
selectivity. This will cause only slightly less BM vibration at the point the signal is 
detected compared to its peak that falls within the DR.
Moore (2004) developed a new version of the TEN test, which expresses all levels in 
dB (HL) rather than dB (SPL), allowing clinicians to measure absolute thresholds 
once. Furthermore, the likelihood of errors is reduced by this new procedure as the 
calibration is such that both TEN level/ERB and the test tone levels correspond to 
those displayed by the audiometer in dB (HL), aiding interpretation of results.
5.4 Clinical uses
The various clinical uses of the TEN test could be enumerated as follows:
(i) The presence or absence of dead regions can have important implications for 
fitting hearing aids and for predicting the likely benefit of hearing aids.
(ii) The test may also be useful in selecting candidates for novel forms of hearing 
aids, such as those incorporating frequency transposition or frequency 
compression.
(iii) The results from TEN test can be used to assess candidacy for cochlear 
implant and in medico-legal work. (Moore et al., 2004)
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6.1 Introduction
The present study evaluated patients undergoing platinum based chemotherapy for 
presence of dead regions within the cochlea using TEN HL (threshold equalising 
noise) test.
6.2 Methods
This thesis was undertaken after full ethical approval was granted from the South 
West Wales Local Research Ethics Committee. (Ref: 05/WMW02/68)
6.3 Study Design
Patients due to have platinum based chemotherapy (Cisplatin, Carboplatin or 
Oxaliplatin) at the chemotherapy day unit at Singleton hospital, Swansea were 
contacted before commencing their chemotherapy, informed about the study and 
invited to participate. All volunteers were provided with a copy of the patient 
information leaflet to read and, if they agreed to take part in the study, were asked to 
sign a consent form. The clinical investigator, Mr. Sandeep Berry, took a short 
clinical history. Patients recruited onto the study were asked to attend the Audiology 
department at Singleton hospital, Swansea to take the TEN (HL) test at a convenient 
time. The study was carried out over a period of 24 months.
6.4 Study Population
Fifty patients awaiting chemotherapy with platinum based drugs at Chemotherapy day 
unit, Singleton hospital, Swansea were recruited and their hearing assessed by 
threshold equalising noise (TEN HL) test for the presence of dead regions before 
initiation of therapy and then at 1, 6 & 12 months post treatment. A note of the drug 
dosage was made but no attempt was made to correlate platinum drug dosage with 
dead regions, as this did not constitute a part of the present study.
All patients recruited satisfied the inclusion and exclusion criteria for the study (listed 
below)
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Inclusions:
■ Age 20-75 years, both male and female patients
■ On chemotherapeutic agents (cisplatin, carboplatin and oxaloplatin) 
Exclusions:
■ Middle or outer ear disease causing conductive hearing loss
■ On other ototoxic drugs (past or present)
■ Congenital hearing loss
■ Patients who do not, or are unable to, consent to the trial
■ Terminally ill patients
6.5 Clinical Examination
Patients who were recruited for the study underwent otoscopic examination prior to 
undergoing pure tone audiometry and TEN (HL) test, neither of which were invasive. 
The tests were done before and after treatment as per protocol.
6.6 Environment and procedure
Testing room, Audiology department
The testing was carried out in a sound proof room within the Audiology department at 
Singleton hospital. The subject was informed about the procedure (PTA & TEN test) 
in detail and was given ample opportunity to ask questions. An otoscopic examination
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was done prior to PTA and TEN (HL) test to exclude any wax or infection. Pure tone 
audiometry was initially performed, followed by TEN (HL) test.
(i) Audiometer
A two-channel audiometer with CD player (GRASON-STADLER; GSI61) was used 
for the PTA and TEN tests.
(ii) Pure Tone Audiometry
Subject was asked to sit on a chair facing away from the audiometer, in a manner to 
promote safety and comfort as well as valid testing. The details of the testing 
procedure were fully explained to the subject and every effort made to ensure that 
they understood them properly. Headphones (TDG 49) were put on the subject’s head 
and a button given to them to press when they heard the sound. Air conduction 
thresholds were tested for frequencies from 500 Hz to 8 KHz, including 750 Hz, 1.5 
KHz & 3 KHz, for both ears. The results were plotted on the audiometry chart. If 
there was a significant difference between air conduction thresholds between two 
ears, then rule of masking were applied and thresholds re-tested and recorded.
The rules of masking used are as follows:
Rule 1: Masking was employed where the difference between the left and right not- 
masked air conduction thresholds is 40 dB
Rule 2: Masking will be needed additionally where Rule 1 has not been applied, but 
where the bone conduction threshold of the better ear is more acute by 40 dB (if supra 
or circum-aural earphones have been used) or 55 dB (if insert earphones have been 
used) or more than the not-masked air conduction threshold attributed to the worse 
ear.
(iii) Theshold equalising noise test (TEN HL)
Following the PTA, TEN test was carried out using a CD, containing noises for 
frequencies (500 Hz, 750 Hz, 1000 Hz, 1500 Hz, 2000 Hz, 3000 Hz & 4000 Hz). A 
two-channel audiometer with CD player was used for this purpose. The test noise was 
initially calibrated prior to testing. TEN (HL) test was carried out as per the 
instructions on the test CD (see below)
(ii) All the cables from CD player to Audiometer were plugged in.
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(iii) Left Output from CD player (A) was fed into left input on the audiometer with
right output from CD player (B) into right input on the audiometer.
(iv) Left (A) input for channel 1 on the audiometer and right (B) input for channel
2 on the audiometer was selected.
(v) Calibration was performed by playing Track 1 on the CD and setting the
audiometer so that both line inputs are continuous (interrupt button on the 
audiometer on), and adjusting VU meters on the audiometer to read OdB.
(vi) The two channels were mixed and directed to right ear first with desired noise
level controlled using channel 1.
The thresholds (masked) for each frequency for the right ear were measured 
and recorded using Tracks 2-8 on the TEN (HL) CD while playing the noise 
continuously (interrupt button on the audiometer for channel 1 pressed). The 
test tone was delivered from channel 2 on the audiometer.
(vii) The TEN (HL) threshold was set at lOdB above the level of the audiometric 
threshold for all the frequencies to be tested.
(viii) The above step was repeated for the left ear.
A dead region at a particular frequency was indicated by a masked threshold that was 
at least lOdB above the absolute threshold and 10 dB above the nominal noise level.
If a dead region was detected for a particular frequency, the absolute threshold was re­
measured using 2dB increments.
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7.1 Introduction
This was a longitudinal study on a group of 50 patients having chemotherapy with 
platinum chemotherapeutic drugs (Cisplatin, Carboplatin & Oxaliplatin) who were 
assessed for the presence of dead regions before initiation of therapy and then at 1,6 
& 12 months post treatment using the threshold equalising noise (TEN HL) test.
7.2 Demographics
Fifty patients were included in the present study.
a. Male: 26
b. Female: 24
The age range was 20- 75 years.
The mean age was 58.8 years and the median age was 60 years
AGE MALE FEMALE
20-40 3 2
41-50 2 4
51-60 9 7
61-70 6 6
71-75 6 5
7.2: Patient distribution
7.3 Results
(i) Type of platinum drugs 
The following table illustrates the patient age groups versus type of platinum drug 
they received.
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AGE
(Years)
CISPLATIN CARBOPLATIN OXALIPLATIN
20-40 5 0 0
41-50 3 1 2
51-60 7 7 2
61-70 3 5 4
71-75 1 7 3
TOTAL 19 20 11
7.3 (i): Patient age groups versus type of platinum drug they received
(ii) Patient data
Classification of patients
Group D (completed upto Pre Ct stage) 
Group C (completed upto 1 month stage) 
Group B (completed upto 6 month stage) 
Group A (completed upto 12 months)
N =
N = 7
....J
0 2 6 8 10 124
N = 2S
(Months)
7.3 (ii): Patient classification versus various groups
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(iii) Patients who completed 12 months of the study (group A)
Twenty-five patients completed the whole study, which included TEN testing prior to 
chemotherapy and then one, six and twelve months post chemotherapy. Out o f the 25 
patients, 21 patients (84%) showed no evidence of dead regions on TEN (HL) test at 
the end of the study.
Four patients out of the 25 (16%) showed evidence of dead regions at various 
intervals of the study with all cases highlighted individually below.
AGE FREQ OF DR PRE CT 1/12 6/12 12/12 DRUG
74/m 3KHz N N N Y; LE Oxaliplatin
66/m 3 KHz N N N Y: LE Carboplatin
58/m 3KHz
4KHz
N
N
Y; LE
Y;
LE
N
N
N
N
Cisplatin
74/m 4KHz Y; LE N N Y; RE Oxaliplatin
Y; RE = dead region in right ear 
Y; LE = dead region in left ear
DR = dead region 
CT = Chemotherapy
7.3 (iii): Patients who completed 12 month of study (Group A)
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(iv) Patients who completed 6 months (group B)
Three patients (6%) completed the study up to the stage of TEN testing at six months 
post chemotherapy. Two out of the three patients showed evidence of dead regions on 
TEN testing at 6 months, but all three patients passed away prior to their twelve 
months TEN testing.
AGE FREQ OF DR PRE CT 1/12 6/12 12/12 DRUG
69/m 4KHz N N Y; RE Died Oxaliplatin
60/m 3 KHz 
4KHz
N
N
N
Y; RE
Y; LE 
Y; RE
Died Carboplatin / 
Cisplatin
Y; RE = dead region in right ear
Y; LE = dead region in left ear
DR = dead region
CT = Chemotherap>
7.3 (iv): Patients who completed up to 6 months stage of the study (Group B)
(v) Patients who completed 1 month (group C)
Seven patients (14%) completed the study up to the stage of TEN testing at one month 
post chemotherapy. Five patients opted out of the study due to ill health and two 
patients passed away. Six out of the seven patients did not reveal any dead regions but 
one showed the presence of dead region on TEN testing.
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AGE FREQ OF DR PRE CT 1/12 6/12 12/12 DRUG
75/f 750Hz N Y; LE Opted out Carboplatin
Y; LE = dead region in left ear
DR = dead region
CT = Chemotherapy
7.3 (v): Patients who completed up to 1 month stage of the study (Group C)
(vi) Patients who only had pre chemotherapy testing (group D)
A total of fifteen patients (30%) completed the study up to the stage of TEN testing 
prior to commencement of chemotherapy. Seven patients opted out of the study due to 
ill health and eight patients passed away. Thirteen out of the fifteen patients did not 
reveal any dead regions but two showed the presence of a dead region on TEN 
testing.
AGE FREQ OF DR PRECT 1/12 6/12 12/12 DRUG
72/f 4KHz Y; LE
Died — Carboplatin
43/f lKHz
1500Hz
2KHz
Y; RE 
Y; BE
Y; RE
Opted out —
Carboplatin
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Y; RE = dead region in right ear 
Y; BE = dead region in both ears
Y; LE = dead region in left ear
DR = dead region 
CT = Chemotherapy
7.3 (vi): Patients who completed up to Pre chemotherapy stage of the study (Group D)
7.4 Interesting observations
A few interesting observations were recorded during the present study. These are 
presented below:
(i) The timing of sensorineural hearing loss for each of the drugs used was noted.
Hearing loss was defined as a worsening of the threshold by more than 10 dB HL at 
500 Hz. IKHz, 2KHz & 4KHz.
Cisplatin (n= 8)
The primary frequency involved was 8KHz.
Right Ear Left Ear Both
PreCT 1
Post CT 1/12 1 2 1
Post CT 6/12 1 1
Post CT 12/12 1
7.4 (i) a: Timing of SNHL & Cisplatin
Carboplatin (n = 8)
The primary frequency involved was 8KHz but one patient also had sensorineural 
hearing loss at 4KHz.
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Right Ear Left Ear Both
PreC T 1 1** 1 ** + 3
Post CT 1/12 1*
Post CT 6/12 1
Post CT 12/12 1
7.4 (i) b: Timing of S VHL & Carboplatin
j ** _ patjent ha(j SNHL at Pre- CT at 500hz /l YJ 2K & 4KHz in both ears and in left 
ear at 8K
1 * = Patient had SNHL at 4KHz at 6/12 post CT in left ear and at 8KHz in left ear 
at 1/12 post CT
Oxaliplatin (n = 6)
The primary frequency involved was 8KHz.
Right Ear Left Ear Both
PreCT 1 1
Post CT1/12 j ** 1*
Post CT 6/12 2
Post CT 12/12 1*
7.4 (i) c: Timing of SNHL & Oxaliplatin
1* = Patient had SNHL at 1/12 post CT in left ear and 6/12 post CT in right ear. 
j ** _ patjent had SNHL at 1/12 post CT in right ear.
(ii) The timing of the occurrence of the dead regions was reviewed for the various 
groups of patients. These cases will be highlighted in the discussion.
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Group A: Completed 12/12
Hearing Threshold 
(dB HL)
Patient Drug Timing of DR Ear Time of DR Pre CT Frequency
1. Oxaliplatin 12/12 post CT Left 55 35 3 KHz
2. Oxaliplatin 12/12 post CT Right 80 60 4KHz
3. Cisplatin 1/12 post CT Left 65 45 3 KHz
\
Cisplatin 1/12 post CT Left 95 70 4KHz
4. Carboplatin 12/12 post CT Left 65 50 3KHz
Group B: Completed 6/12
Hearing Threshold 
(dB HL)
Patient Drug Timing of DR Ear Time Of 
DR
Pre CT Frequency
5 ^ - Cisplatin 6/12 post CT Left 70 65 3 KHz
Cisplatin 1/12 post CT Right 55 50 4KHz
6. Oxaliplatin 6/12 post CT Right 90 55 4KHz
Group C: Completed 1/12
Hearing Threshold 
(dB HL)
Patient Drug Timing of DR Ear Time Of 
DR
Pre CT Frequency
7. Carboplatin 1/12 post CT Left 40 30 750Hz
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(iii) Five patients revealed evidence of dead regions on TEN testing at pre - 
chemotherapy stage. In two patients, the dead region improved at 1/12 post CT, while 
in one patient the dead region persisted up to 12/12 post CT. The remaining two 
patients passed away prior to the next stage of testing. None of the five patients had 
any previous history of chemotherapy with platinum based drugs, loud noise 
exposure, radiotherapy or use of any ototoxic drug.
Patient Drug Ear Hearing 
Threshold 
(dB HL) at the 
time of DR
Frequency
1. Carboplatin Right 80 lKHz
Right 85 1500HZ
Left 75 1500HZ
Right 75 2KHz
2. Carboplatin Left 50 4KHz
3. Oxaliplatin Left 60 4KHz
4. Carboplatin Left 75 4KHz
5. Carboplatin Right 85 4KHz
7.4 (iii): Patients with dead region at Pre CT stage versus drugs
(iv) Dead regions were identified in 7 patients at different stages of TEN testing. The 
variability of the occurrence of the dead regions was an important observation made 
during this study.
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Patient Timing of DR Drug Associated Factors
1. 12/12 post CT Oxaliplatin None
2. 12/12 post CT Carboplatin None
3
1/12 post CT Cisplatin None
1/12 post CT Cisplatin None
4. 12/12 post CT Oxaliplatin None
5 . ^ - -  1/12 post CT Cisplatin Patient also received
\ \ carboplatin
v 6/12 post CT Cisplatin
6. 6/12 post CT Oxaliplatin None
7. 1/12 post CT Carboplatin None
7.4 (iv): Dead region occurrence & variability
(v) 3 patients in total were noted to have dead regions at different stages of the TEN 
testing, of which 2 patients had this finding at pre CT stage, while in the remaining 1 
subject it, was at 1/12 post CT. In all three, the dead regions resolved spontaneously 
at the next stage of testing. Hearing thresholds at the time of occurrence and 
disappearance of dead region were noted.
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Hearing Threshold 
(dB HL)
Age/ Drug Ear DR DR DR DR Frequency
Sex Present absent Present Absent
74/M Oxaliplatin Left Pre CT 1/12 60 80 4KHz
58/M Cisplatin Left 1/12 6/12 65 50 3 KHz
Left 1/12 6/12 95 70 4KHz
66/M Carboplatin Left Pre CT 1/12 75 70 4 KHz
7.4 (v): Spontaneous resolution of dead region versus drugs
(vi) Three patients who received Oxaliplatin showed presence of dead region on TEN 
testing at six months (n=l) and twelve months (n=2) respectively. In one subject, dead 
region was observed at pre chemotherapy testing but resolved at the time of one month 
post chemotherapy testing. On reviewing the literature (search term: Oxaliplatin AND / 
OR hearing loss: 1966 to date), there has been no report of any case of oxaliplatin 
induced hearing loss.
Hearing Threshold 
(dB HL)
Patient Age/Sex Timing of DR Ear Time of DR Pre CT Frequency
1. 69/M 1/12 post CT Right 90 55 4KHz
2. 74/M 12/12 post CT Right 80 60 4KHz
3. 74/M 12/12 post CT Left 55 35 3KHZ
7.4 (vi): Patients who received Oxaliplatin & dead regions
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7.5 List of patients with dead regions: section 7.4 (ii)
Case 1:
74 year old gentleman who underwent chemotherapy with Oxaliplatin post surgical 
excision of his bowel cancer, showed evidence of dead region at 3000 Hz at twelve 
month testing post chemotherapy in his left ear. He had six cycles of chemotherapy 
and his threshold (dB HL) prior to commencement of chemotherapy was 35 and at 
time o f dead region was 55.
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Case 2:
74-year-old gentleman, who underwent chemotherapy with Oxaliplatin post surgical 
excision of his bowel cancer, showed evidence of dead region at 4000 Hz at twelve­
month testing post chemotherapy in his right ear. He had seven cycles of 
chemotherapy along with capecitabine and his threshold (dB HL) prior to 
commencement of chemotherapy was 60 and at time of dead region was 80.
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Case 3:
58-year-old gentleman, who underwent chemotherapy with Cisplatin post surgical 
excision of his laryngeal cancer, showed evidence of dead region at 3000 & 4000 Hz 
at one month testing post chemotherapy in his left ear. He had five cycles of 
chemotherapy and his threshold (dB HL) prior to commencement of chemotherapy 
was 45 & 70 and at time of dead region was 65 & 95 respectively.
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Case 4:
66 year old gentleman, who underwent chemotherapy with carboplatin for recurrent 
lung cancer, showed evidence of dead region at 3000 Hz at six and twelve month 
testing post chemotherapy in his left ear. He had four cycles o f chemotherapy along 
with radiotherapy and his threshold (dB HL) prior to commencement of 
chemotherapy was 55 and at time o f dead region was 65
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Case 5:
69-year-old gentleman presented with metastatic bowel cancer and underwent 
extended hemicolectomy followed by three cycles of chemotherapy with Oxaliplatin. 
Dead region was found at six month testing in his right ear at 4000 Hz. The threshold 
at pre chemotherapy testing was 45dB HL and at the time of dead region was 90 dB 
HL. He passed away prior to his twelve-month testing.
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Case 6:
60-year-old gentleman with advanced lung cancer and had chemotherapy with 
cisplatin (3 cycles) and carboplatin (4 cycles).
He developed dead region at one-month post chemotherapy testing in his right ear at 
4000 Hz. which persisted at six-month testing stage. The threshold at pre 
chemotherapy testing was 50 dB HL and at the time of dead region was 55 dB HL. He 
also had dead region in his left ear at six-month post chemotherapy stage testing at 
3000 Hz and the threshold at pre chemotherapy testing was 65dB HL and at the time 
o f dead region was 70 dB HL. He passed away prior to his twelve-month testing.
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Case 7:
75-year-old lady, who had ovarian cancer, underwent debulking and chemotherapy 
with carboplatin (six cycles). She developed dead region in her left ear at 750Hz at 
one month post chemotherapy stage testing. She opted out of the study due to ill 
health and hence was not tested at six and twelve months post chemotherapy. Her 
threshold in the left ear pre chemotherapy and at time of dead region was 40dB HL.
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8.1 Introduction
A prospective longitudinal study to identify the presence of dead regions in the 
cochlea of patients who had chemotherapy with platinum based drugs using TEN test 
was conducted. Fifty patients having chemotherapy with platinum chemotherapeutic 
drugs (Cisplatin, Carboplatin & Oxaliplatin) were recruited and their hearing assessed 
by Pure Tone Audiometry and TEN (HL) test for the presence of dead regions before 
initiation of therapy and then at 1, 6 & 12 months post treatment.
Inclusion criteria have been discussed above.
8.2 TEN test and dead regions
(i) Background
Regions in the cochlea with no or very minimal functioning inner 
hair cells are termed Dead regions. The fundamental basis of these regions has been 
mentioned in the literature. Schuknecht (1993) after extensive work on the temporal 
bones of people with hearing loss, showed that there could be an association between 
hearing loss and damage to inner and outer hair cells. Discrimination of the sounds, 
including speech, may be affected when the loss of inner hair cells exceeds 50%.
The extent of a dead region has previously been defined according to non-functioning 
location or distance along the BM, for example extending from 0-12 mm for a basal 
dead region (Moore, 2001; Moore, 2004). As the cochlea is known to demonstrate 
frequency-place specificity, a dead region may be defined by characteristic frequency 
normally associated with that region, e.g. extending from 4,000 to 10,000 Hz (Moore 
et al., 2000). Moore (2001) later identified a weakness in this definition: damage to 
OHCs, often associated with IHC loss, may generate shifts in the characteristic 
frequency along the BM, causing the characteristic frequency to move relative to their 
normative values. He devised an alternative definition incorporating these changes;
“a dead region is defined in terms of the characteristic frequencies of the IHCs and/or 
neurons immediately adjacent to the dead region” (Moore, 2001). This new definition 
simplifies analysis of dead region boundaries when performing psychophysical tests 
(Moore, 2001).
Whilst basilar membrane vibration information arising within a dead region itself is 
not transmitted to the brain, a tone of frequency falling within a dead region may still
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be detected. An apical or basal spread of the vibration pattern to adjacent functioning 
IHCs and/or neurons of a different characteristic frequency will result provided the 
sound is of a sufficient intensity (Moore and Alcantara, 2001). Such detection of 
sounds is referred to as off-place or off-frequency listening (Moore, 2004). For 
example, where a dead region starts at 1 KHz and extends above this frequency along 
the basilar membrane, sufficiently intense tones of between 1.0 KHz-1.5 KHz will be 
detected due to a downward spread of vibration to healthier basilar membrane 
locations tuned to just below 1 KHz (Moore, 2004).
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Figure 8.2 (i) Envelopes of BM vibration patterns are illustrated for a hypothetical ear 
with a DR extending from 1 KHz upwards (indicated by the shaded area) and 
moderate low-frequency hearing loss (the horizontal dashed line represents threshold 
vibration level): Moore 2004, p. 99
Moore (2004) further identifies that where IHCs and/or neurons are functioning less 
efficiently, or reduced in number, off-frequency listening may occur. Whilst such 
places upon the basilar membrane are not strictly ‘dead', the larger stimulus necessary 
to produce basilar membrane vibration in that region will cause excitation of adjacent, 
healthier, more efficiently functioning IHCs / neurones. Clinical procedures used to
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diagnose dead regions are based upon detection of off-frequency listening. It is also 
recognized however, that in instances where hearing impairments arise at adjacent 
regions of the basilar membrane, it may no longer be possible to determine a dead 
region through this process (Munro, 2007).
(ii) Timing & variability of occurrence
The variability of the timing of occurrence of dead regions was an interesting finding 
of the present study. To date, there has been no study looking at the presence of dead 
regions in patients who have had platinum based chemotherapy.
All 7 (9 ears) patients, who demonstrated dead regions, did show worsening of their 
hearing thresholds. Their hearing thresholds prior to chemotherapy ranged between 35 
and 60 dB HL and at the time of dead region, the hearing thresholds were between 40 
and 95 dB HL. Vinay & Moore (2007) described a high incidence of dead regions in 
adults with sensorineural hearing impairment, especially for frequencies at which the 
hearing loss exceeds 70 dB HL. In the present study, 6 out of 7 patients showed 
presence of dead regions at 3000 Hz and 4000 Hz. Aazh & Moore (2007) tested 98 
people with absolute thresholds between 60 and 85 dB HL at 4 KHz using the 
threshold equalizing noise test for presence of dead regions, of which 36 had a dead 
region at 4 KHz. They found no statistically significant difference in the slope of the 
audiogram or PTA between ears with and without dead regions and the mean absolute 
threshold at 4 KHz was significantly higher for the group with dead region than for 
the group without dead region. The prevalence of dead region exceeded 50% for 
hearing losses greater than 70 dB.
(iii) Presence at pre-chemotherapy stage
It has been reported in the literature about the association between a presence of dead 
regions, slope of the audiogram and degree of hearing loss. Vinay and Moore (2007) 
reviewed 308 patients with sensorineural loss for evidence of dead regions and found 
that for each test frequency, 59% or more of ears had a dead region when the absolute 
threshold was above 70 dB HL. A very steep slope of the audiogram is suggestive of a 
high-frequency dead region but does not provide a reliable diagnostic method. On the 
other hand, Aazh and Moore (2007) found no statistically significant difference in the 
slope of the audiogram between ears with and without dead regions. Jacob (2006) 
assessed 43 patients (76 ears) with high frequency sensorineural loss and identified
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dead regions in 92% of seventy-six tested ears. This was in agreement with previous 
results that suggested a significant prevalence of dead regions in individuals with 
sloping sensorineural hearing loss (Moore, 2001 ; Vickers et al., 2001). Summers 
(2003) used TEN and psychophysical tuning curves (PTC) to assess eighteen ears 
with moderate to severe sloping sensorineural hearing loss. Both tests were able to 
identify the presence or absence of dead regions in ten out of eighteen ears (56%). 
They concluded that a 56% agreement rate between two tests showed that at least one 
of them was partially reliable as a diagnostic tool. However, due to unrelated factors 
to the presence of dead regions, may lead to excess masking and not produce tip shifts 
in PTC and hence, PTC shifts are more reliable than TEN test when there is a 
disagreement between results of both tests. Davies (2009) investigated the prevalence 
of cochlear dead regions in 62 patients with sensorineural hearing loss. TEN test was 
used to assess the presence or absence of dead regions with prevalence of cochlear 
dead regions being 14.5% among patients. Absolute thresholds at 4 KHz tended to be 
higher in the patients with dead regions, but presence or absence of dead regions was 
not related to the slope of the audiogram or pure tone average of 500hz, 1kHz, 2kHz 
& 4kHz.
However, the present study highlighted an interesting finding of presence of dead 
regions in five patients at pre- chemotherapy stage of testing without any of them 
having any previous history of chemotherapy with platinum based drugs, loud noise 
exposure, radiotherapy or use of any ototoxic drugs. Their hearing thresholds, at time 
of dead region, ranged between 60 and 85 dB HL and frequencies involved were 
4KHz and 8 KHz, except in one case where frequencies between 1 KHz to 2 KHz 
were affected.
One such case is highlighted below as an example.
L
ev
el
 (
dB
 
H
L
)
74
Frequency (Hz)
250 500 750 1000 1500 2000 3000 4000 8000
-10
0
10
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120
Patient with dead region at Pre chemotherapy testing
(iv) Spontaneous resolution
Another notable finding was the spontaneous resolution of the dead regions in three 
patients with improvement of hearing threshold in all but one case. In principle, the 
IHCs and/or neurones could be completely non-functional as a result of drugs or 
metabolic disturbance, but recover when the drug is removed or there is a recovery 
from metabolic disturbance (Moore, 2009-personal communication). Smoorenburg 
(1999) conducted studies to assess if cisplatin induced ototoxicity can recover 
spontaneously and measured response with electrocochleography. They strongly 
suggested that spontaneous recovery of cochlear injury can occur in the mature 
mammalian cochlea and it may be possible to stimulate recovery from acute hearing 
loss using neuropeptides. Monitoring of hearing loss during chemotherapy, account of
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total dosage received, co-administration of chemoprotective agents and allowing 
substantial clinically acceptable breaks between chemotherapy cycles may allow the 
cochlea to recover spontaneously from the ototoxic effects of chemotherapeutic 
agents.
(v) Oxaliplatin & dead regions
Dead regions were observed in three patients who received Oxaliplatin, with none of 
them having previous history of hearing loss, use of ototoxic drugs or loud noise 
exposure. There was worsening of their audiometric threshold, at the frequency of 
dead region, in comparison to the pre-chemotherapy stage by more than 20 dB HL in 
two patients. In one patient, the dead region spontaneously improved on further 
testing. On reviewing the literature (search term: Oxaliplatin AND / OR hearing loss: 
1966 to date) , there has been only one report of a case of oxaliplatin induced hearing 
loss. Malhotra (2010) reported unilateral hearing loss in a 70-year-old woman who 
was undergoing postoperative chemotherapy for rectal adenocarcinoma and had 
developed hearing loss following a single infusion of Oxaliplatin, which persisted and 
never recovered. Hellberg (2009) conducted a study to determine why Oxaliplatin has 
negligible otoxicity when compared with cisplatin, despite both being platinum 
compounds. They measured the amount of cisplatin and oxaliplatin that reached the 
cochlea in guinea pigs following intravenous dosing of each drug and concluded that 
cisplatin, and not Oxaliplatin, induced apoptosis, which involved superoxide-related 
pathways. There was a lower cochlear uptake of oxaliplatin than cisplatin, thereby 
explaining oxaliplatin’s lower ototoxic potential.
8.3 Limitations
During the present study, dead regions were identified in 7 patients (9 ears) at various 
stages of TEN testing. The variability of the occurrence of the dead regions was an 
important observation made during this study. Cairns (2007) reviewed short-term test- 
retest repeatability of the TEN (HL) test on 15 teenagers (mean age 14 years) with 
long-standing severe-to-profound hearing impairment, and 20 adults (mean age 74 
years) with moderate- to-severe hearing impairment using the same equipment and 
procedure, after an interval of less than five days. They found that only 2 ears (8%) in 
teenagers and 3(7.5%) in adults changed category on retesting and overall the TEN
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test repeatability was good. They concluded that the majority of ears that changed 
category on retest had just met the dead-region criteria at an isolated frequency and 
hence immediate retest is worthwhile in such cases. In the present study, all the cases 
met criteria of dead region for the TEN test (Moore, 2004) and it was not possible to 
recall them for TEN test repeatability, as the cohort of patients comprised people with 
cancer.
8.4 Future implications
Identification of dead regions in 7 patients (9 ears) was an important outcome of the 
present study, as it highlighted that platinum based drugs could cause dead regions. 
TEN (HL) test, therefore, could be valuable in monitoring hearing loss in patients 
receiving platinum based chemotherapy. Moore (2004) suggested that there is no 
value in amplifying frequencies that lie within the dead region. However, in people 
with high frequency hearing loss, as is the case with people having platinum based 
chemotherapy, applying amplification for frequencies up to 50% higher than the 
lower edge frequency of the dead region may be of benefit. This can help to avoid 
distortion and acoustic feedback, thereby allowing a better assessment and fitting of 
hearing aids. Accurate documentation of dead regions using the TEN (HL) test would 
help in selection of candidates for novel forms of hearing aids and their rehabilitation.
8.5 Further research
The present study highlighted some interesting observations. These were:
(i) Platinum based chemotherapy does lead to dead regions but at variable times.
(ii) Oxaliplatin can lead to dead regions
(iii) Dead regions can spontaneously resolve in patients on chemotherapy 
The newer version of the TEN test is a fast and efficient way of detecting dead 
regions (Moore, 2004). However, further research is required to verify the suitability 
of TEN (HL) criteria for dead region detection in various age groups and degrees of 
SNHL (Cairns et al., 2007). It is acknowledged the TEN test (HL) is relatively quick 
and useful in establishing the presence of dead regions, yet it only approximates the 
value of the frequency at the edge of dead region (fe ), provided appropriate measures 
are taken to prevent the detection of beats and simple difference tones,
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Psychophysical Tuning Curve (PTC) are useful in estimating femore precisely, 
particularly where the TEN may produce borderline results (Moore et al., 2000; 
Moore and Alcantara, 2001; Vestergaard, 2003; Kluk and Moore, 2006).
Kluk and Moore (2006) and Sek (2005) suggested that fast PTCs be more readily 
available to clinicians for clinical practice due to their being quick to perform and 
precise fe estimate, although not always the case. TEN and PTCs (traditional or fast) 
should be used in combination, where dead regions are suspected, thus quickening the 
process of identifying dead regions and their boundaries.
Further research needs to be done to look at Oxaliplatin and dead regions, as well as 
the spontaneous resolution of the dead regions by combining both TEN (HL) test and 
fast PTCs.
8.6 Conclusion
In summary, the primary aim of this study was to identify dead regions in the cochlea 
in patients who had chemotherapy with platinum based drugs using the Threshold 
Equalising noise (TEN HL) test. Fifty patients were recruited for the study. The 
present study highlighted some interesting observations. These were:
(i) Platinum based chemotherapy administration led to dead regions in seven patients.
(ii) Dead regions were observed in three patients who received Oxaliplatin
(iii) Spontaneous resolution of the dead regions was observed in three patients, who 
received platinum based chemotherapy.
(iv) Dead regions occurred at different times during the study and did not have a 
specific pattern
The above findings were very interesting to note and notably will require further 
research.
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APPENDIX
1. Patient information sheet
1. Study title
Evaluation of TEN HL (threshold equalising noise) test to localise dead regions 
within the cochlea in patients who have had chemotherapy with platinum based drugs.
2. Invitation paragraph
You are being invited to take part in a research study. Before you make your decision, 
it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and to discuss it 
with friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you 
wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitled 'Medical 
Research and You'. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from CERES, 
PO Box 1365, London N16 OBW.
Thank you for reading this
3. What is the purpose of the study?
Cisplatin and carboplatin are highly effective drugs, that are used in the treatment of 
your cancer. As you know there are several side effects of these drugs. One of which 
is the possibility of hearing loss. They affect the hearing by damaging hair cells in the 
cochlea (organ of hearing). Our study is to assess the amount of hearing loss, if any 
by using a simple hearing test called the TEN (Threshold Equalizing Noise) test.
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4. Why have I been chosen?
Any patient who is on platinum based drugs such as yourself may be invited to take 
part in this study. We aim to recruit 50 patients over a period of 24 months for a long 
term study.
5. Do I have to take part?
Your participation in this study is entirely voluntary. If you do decide to take part you 
will be given this information sheet to keep and will be asked to sign a consent form.
You are under no pressure to take part and may withdraw from the study if you so 
desire at any time without having to explain why. This will in no way affect the 
standard of care you receive.
6. What will happen to me if I take part?
You will be required to come for the hearing test, at a time convenient to you once 
before and once one month after completion of your treatment. There will be two 
more visits 6 months and 12 months following completion of your treatment (four 
tests in all). The hearing test will be done in the ENT outpatients department,
Singleton Hospital by myself (Mr.S.Berry).
You will not need to visit your GP more often than for your usual treatment
7. What do I have to do?
Taking part in the study does not require you to do anything different from other 
patients who undergo the same treatment apart from having hearing tests.
8. What is the drug or procedure that is being tested?
The aim of the study is to find out the effects of platinum based drugs on hearing by 
using a simple hearing test as mentioned above.
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9. What are the side effects of any treatment received when taking part?
None
10. What are the possible disadvantages and risks of taking part?
None
11. What are the possible benefits of taking part?
There is no intended clinical benefit to you from taking part in the study. But the 
information we get from the study may help other patients in the future.
12. What if new information becomes available?
If new information becomes available about the effects of anti-cancer drugs on 
cochlea, this will be conveyed to you in the following visit to the hospital. The 
planned follow up contacts with you will proceed as normal.
13. What happens when the research study stops?
When the research ends, we will tell you about our findings and discuss with you at 
that time any further treatment you may require.
14. What if something goes wrong?
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence, then 
you may have grounds for a legal action but you may have to pay for it. Regardless 
of this, if you wish to complain, or have any concerns about any aspect of the way 
you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you.
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15. Will my taking part in this study be kept confidential?
All information that is collected about you during the course of the research will be 
kept strictly confidential. Any information about you which leaves the hospital will 
have your name and address removed so that you cannot be identified.
16. What will happen to the results of the research study?
We hope to complete the study in 24 months time. We will then produce a report and 
papers will be written for publication in medical journals. Your identity will remain 
confidential in all these reports.
In addition we will write to tell you the main results of our research.
17. Contact for Further Information
Mr Sandeep Berry, SpR ENT 07977118685
Mr Simon Browning, Consultant ENT Surgeon 01792205666 ext: 5567
8. Patient consent sheet 
Centre Number: :
Study Number:
Patient Identification Number for this trial:
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2. Patient consent sheet
CONSENT FORM
Title of Project:
Evaluation of TEN (threshold equalising noise) test to localise dead regions within the 
cochlea in patients who have had chemotherapy with platinum based drugs.
Name of Researcher: Mr. S. Berry
Please initial box
1. I confirm that I have read and understand the information sheet for the above 
study and have had the opportunity to ask questions.
□
2. I understand that my participation is voluntary and that I am free to withdraw at 
any without giving any reason, without my medical care or legal rights being affected.
□
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to my taking 
part in research. I give permission for these individuals to have access to my records.
□
4. I agree to take part in the above study.
□
Name of Patient 
Date
Signature
Name of Person taking consent Date
(if different from researcher)
Signature
Researcher Date
Signature
